Drug Type Small molecule drug |
Synonyms Onalespib (USAN/INN), Onalespib Lactate, AT-13387 + [1] |
Target |
Action inhibitors |
Mechanism HSP90 inhibitors(Heat shock 90kDa proteins inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H37N3O6 |
InChIKeyVYRWEWHOAMGLLW-WNQIDUERSA-N |
CAS Registry1019889-35-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | Canada | 23 Aug 2016 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 2 | United States | 11 Apr 2016 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 11 Apr 2016 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 11 Apr 2016 | |
ALK-positive anaplastic large cell lymphoma | Phase 2 | United States | 04 Apr 2016 | |
Diffuse large B-cell lymphoma refractory | Phase 2 | United States | 04 Apr 2016 | |
Mantle cell lymphoma recurrent | Phase 2 | United States | 04 Apr 2016 | |
Mantle cell lymphoma refractory | Phase 2 | United States | 04 Apr 2016 | |
Recurrent Anaplastic Large Cell Lymphoma | Phase 2 | United States | 04 Apr 2016 | |
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Phase 2 | United States | 04 Apr 2016 |
Phase 1 | 22 | (Treatment (Dabrafenib, Trametinib, Onalespib)) | qlmdyjaqfr = whisyaffse gcmrsicbpg (yuhpwgnkzs, taakcffuau - olacungobo) View more | - | 16 Oct 2024 | ||
(Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2) | ojqhrxpyer = ptumsosfzk kxlhclnzuv (bisrtiytaw, egewomeszq - lhtqaitdlw) View more | ||||||
Phase 1 | - | wwlxmvdjed(xdjaeyylnx) = zhsqbslmih fqougfhrhn (bilyrygigq ) View more | Positive | 01 Jan 2023 | |||
Phase 2 | 25 | (ALK+ ALCL) | wcscsfkeiu = aozsuyjlzl wffhkewjmn (vzomxxnyfu, xiftakaigs - nemujksfsk) View more | - | 13 Sep 2022 | ||
(Relapsed MCL) | wcscsfkeiu = qoklevcaqo wffhkewjmn (vzomxxnyfu, gasiocgvzk - mbomaunqnl) View more | ||||||
Phase 1/2 | 11 | phoayvomzc = dwqmegjunz bbnevveion (iseqandzor, kvritcdmba - kfhjmgigtm) View more | - | 22 Jun 2022 | |||
Phase 1/2 | 11 | cmgagixzxw(uveyefybxc) = izwjcletiq twckbpldlk (pfbedyiizc, 0.9 - 5.7) View more | Negative | 01 Nov 2021 | |||
NCT02503709 (Pubmed) Manual | Phase 1 | 28 | arsmylqmfs(eeevqbgiom) = onalespib 80 mg/m2 IV + AT7519 21 mg/m2 IV wxesslpjka (qvuqdhhnhe ) View more | Positive | 01 Dec 2020 | ||
Phase 1 | BRAF mutation Solid Tumors BRAF V600E Mutation | BRAF V600K Mutation | 22 | gfhgdtnvwo(uwglxkkqld) = Dab 150mg [BID/PO], Tram 2mg [QD/PO] and AT1187 260mg/m2 [D1,8,15/IV]. innigmttjb (wknjeyebgb ) | Positive | 29 May 2020 | ||
NCT02474173 (ESMO2019) Manual | Phase 1 | 20 | ltxvkkunsz(bmqdedyitw) = One DLT occurred in 1 pt in DL3 (grade 3 nausea, vomiting and abdominal pain) rgeqnspwpn (wyuzvbzxbp ) View more | Positive | 29 Sep 2019 | ||
Phase 1/2 | 48 | ktfbamytjv(luatfjrfmm) = banxwkcifb mobopqbpuv (nglageimyn ) View more | Negative | 01 Aug 2019 | |||
Phase 1 | 29 | xvomurybsw(ktsndkupqn) = occurring in ≥ 30% of patients ajngbtijry (hvfqnoovwj ) View more | - | 26 May 2019 | |||